Octreotide treatment for sulfonylurea-induced hypoglycaemia.
Crawford
Bronwyn A L
BA
Perera
Channa
C
D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005907:Gliclazide / Q000627:therapeutic use; D005905:Glyburide / Q000627:therapeutic use; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced* / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008297:Male; D015282:Octreotide / Q000627:therapeutic use*; D013453:Sulfonylurea Compounds / Q000009:adverse effects*; D016896:Treatment Outcome
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D005907:Gliclazide; D015282:Octreotide; D005905:Glyburide